This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TFF Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Craig Jalbert

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

AMMINISTRATORE DELEGATO

Craig Jalbert (62 yo)

less than a year

Mandato

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Jalbert	CEO, President	less than a year	Nessun dato	Nessun dato
Anthony Hickey	Chairman of the Scientific Advisory Board and Senior Research & Development Advisor	1.9yrs	Nessun dato	Nessun dato
David Denning	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Drew Weissman	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Ted Ross	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Mike Saag	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
David Cornfield	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Jay Peters	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TFFP sono considerati esperti (durata media dell'incarico 3.3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/15 03:36
Prezzo dell'azione a fine giornata	2024/12/12 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

TFF Pharmaceuticals, Inc. è coperta da 4 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Mayank Mamtani	B. Riley Securities, Inc.
Raghuram Selvaraju	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group

This company listing is no longer active

TFF Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Recent updates

TFF Pharmaceuticals, Inc.(NasdaqCM:TFFP) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer

New major risk - Share price stability

New major risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 77%

TFF Pharmaceuticals, Inc. Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection

Consensus revenue estimates decrease by 29%, EPS upgraded

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 39%

No longer forecast to breakeven

TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs

New major risk - Share price stability

TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference

Forecast to breakeven in 2026

New minor risk - Profitability

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 40%

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Consensus revenue estimates increase by 37%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

No longer forecast to breakeven

No longer forecast to breakeven

Key Executive recently bought US$132k worth of stock

Consensus revenue estimates increase by 16%

TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer

Forecast to breakeven in 2025

Key Executive recently bought US$53k worth of stock

TFF Pharmaceuticals Announces Leadership Transition

Consensus revenue estimates increase by 98%

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

Price target decreased to US$16.00

TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Independent Director exercised options and sold US$72k worth of stock

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022

TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation

TFF Pharma: The Potential Is Still Very Much Present

Consensus revenue estimates fall by 84%

No longer forecast to breakeven